Cytodyn Distribution Agreement

By September 16, 2021 Uncategorized No Comments

(CYDY) announced an exclusive distribution and delivery agreement with American Regent for its Covid 19 leronlimab trial treatment in the United States. About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for several therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a crucial role in HIV`s ability to penetrate and infect healthy T cells. The CCR5 receptor also appears to be involved in tumor metastases and immune diseases such as GvHD and NASH. CytoDyn has completed a Phase 3 approval study of leronlimab in combination with standard antiretroviral therapy in HIV-infected patients with therapeutic experience. .